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Abstract
Background: Numerous studies have described the immunosuppressive capacity of mesenchymal stem cells (MSC) but
these studies use mixtures of heterogeneous progenitor cells for in vitro expansion. Recently, multipotent MSC have been
prospectively identified in murine bone marrow (BM) on the basis of PDFGRa+ SCA1+ CD45− TER119− (PαS) expression
but the immunomodulatory capacity of these MSC is unknown.
Methods: We isolated PαS MSC by high-purity FACS sorting of murine BM and after in vitro expansion we analyzed the
in vivo immunomodulatory activity during acute pneumonia. PαS MSC (1 × 106) were applied intratracheally 4 h after
acute respiratory Klebsiella pneumoniae induced infection.
Results: PαS MSC treatment resulted in significantly reduced alveolitis and protein leakage in comparison to mock-treated
controls. PαS MSC-treated mice exhibited significantly reduced alveolar TNF-α and IL-12p70 expression, while IL-10
expression was unaffected. Dissection of respiratory dendritic cell (DC) subsets by multiparameter flow cytometry revealed
significantly reduced lung DC infiltration and significantly reduced CD86 costimulatory expression on lung CD103+ DC in
PαS MSC-treated mice. In the post-acute phase of pneumonia, PαS MSC-treated animals exhibited significantly reduced
respiratory IL-17+ CD4+ T cells and IFN-γ+ CD4+ T cells. Moreover, PαS MSC treatment significantly improved overall
pneumonia survival and did not increase bacterial load.
Conclusion: In this study we demonstrated for the first time the feasibility and in vivo immunomodulatory capacity of
prospectively defined MSC in pneumonia.
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Background
The use of surface markers, such as CD34 for the pro-
spective identification and isolation of hematopoietic stem
cells (HSC) has fundamentally improved the clinical
development and standardization of stem cell transplant-
ation [1–3]. In contrast, most, if not all knowledge regard-
ing the immunosuppressive capacity of mesenchymal
stem cells (MSC) derives from studies using starting
cultures of mixed cell populations [4, 5]. Therefore, the
International Society for Cellular Therapy has published
criteria for the definition of in vitro expanded heteroge-
neous MSC including positivity for CD73, CD90 and
CD105, negativity for hematopoietic surfaces markers and
other parameters [6]. Although these criteria are helpful
to facilitate the comparison of heterogeneous MSC cul-
tures, the prospective identification and direct isolation of
homogenous MSC populations on the basis of surface
markers will improve the standardization, comparability
and reproducibility of MSC research.
Morikawa et al. has recently identified surface markers for
the prospective identification of purified murine multipotent
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MSC from adult BM [7, 8]. Their results suggested that the
co-expression of Platelet-derived growth factor receptor α
(PDFGRα, CD140a) and stem-cell antigen 1 (Sca-1) on
CD45 and TER119 negative BM cells effectively identifies
primary MSC and these were termed double positive
PDFGRa+ SCA1+ CD45− TER119− (PαS) MSC [7]. PαS
MSC exhibited the highest numbers of colonies in a
colony-forming unit-fibroblasts (CFU-F) assay and
represented the only BM subset yielding MSC typical
fibroblast/spindle-shaped cells. Only PαS cultures dem-
onstrated a potent multilineage differentiation capacity
into adipogenic, chondrogenic and osteogenic lineages
indicating a high enrichment for MSC [7].
Heterogeneous results have been reported with regard to
the immunosuppressive capacity of MSC [9, 10]. With
respect to T cells, different pathways have been suggested
including the direct inhibition of T effector cell proliferation
and promotion of regulatory Tcells [5]. Similarly, MSC have
been suggested to inhibit the cytotoxicity of NK cells and
CD8+ T lymphocytes [11, 12]. With respect to dendritic
cells (DC), MSC inhibit the monocyte-derived DC differ-
entiation and suppress the costimulatory molecule expres-
sion, the pro-inflammatory cytokines IL12p70 and TNF-α
as well as the priming of responder T cells [5, 13, 14].
However, an increasing number of reports indicate that
MSC are not immunosuppressive by themselves but can
also exert immunostimulatory activity. For instance, Water-
man et al. suggested that MSC can be polarized in im-
munosuppressive MSC1 or pro-inflammatory MSC2 by
TLR3 and TLR4 triggering [15]. Moreover, some groups
have reported accelerated heart allograft rejection and a
failure to inhibit graft-versus-host disease after MSC treat-
ment [16, 17]. Potential mechanisms of immunostimulatory
MSC may be related to the release of activatory exosomes
or CCL2 production.
With respect to these heterogeneous immunological re-
sults and the increasing number of MSC studies suggesting
therapeutic activity in acute pneumonia [18–20] the object-
ive of this study was to investigate the in vivo immunomod-
ulatory capacity of prospectively defined MSC in an animal
model of gram negative pneumonia. Furthermore, to ad-
dress more precisely the impact of this treatment on respira-
tory cellular inflammation we have used multiparameter
flow cytometry allowing the dissection of key respiratory
leukocyte subsets after MSC therapy [21–23].
Methods
Mice, Klebsiella pneumoniae infection and MSC treatment
Specific-pathogen-free C57BL/6 (C57BL/6NCrl) and B6.Cg-
Tg(TcraTcrb)425Cbn/J mice (20–25 g each) were purchased
from Charles River, Germany and maintained under
specific-pathogen-free conditions. The mice were infected
intratracheally with 3.5 × 105 CFU of Klebsiella pneumoniae
(K. pneumoniae) serotype 2 (American Type Culture
Collection (ATCC) 43816) in 50 μl sterile 0.9 % NaCl as pre-
viously described [23]. Four hours p.i. the anesthetized mice
received 1 × 106 washed PαS MSC in 50 μl 0.9 % NaCl
intratracheally and were analyzed at the indicated time
points (KpN/MSC). The control mice were treated identi-
cally but received 50 μl 0.9 % NaCl (KpN/NaCl). Some mice
received 1 × 106 washed mouse lung fibroblasts
(MLg;ATCC CCL-206) in 50 μl 0.9 % NaCl and were indi-
cated as such (KpN/MLg). Experiments were approved by
the regional animal authority board (#75/2011).
BM preparation, PαS MSC sorting and in vitro expansion
Femura and tibiae were prepared as previously described
with minor modifications [7]. The bone fragments were
collected and digested for 1 h at 37 °C in alpha-MEM with
L-Glutamine (PAN Biotech, Germany), 10 % FBS (PAA,
Germany), 1 % penicillin/streptomycin (PAN Biotech)
containing 3.92 U/ml collagenase (Wako Chemicals, Japan),
10 mM Hepes (Gibco, Germany) and 3 mM CaCl2. The
cell suspension was filtered through a 70 μm cell strainer
(BD Falcon, Germany) and collected by centrifugation at
400 g for 5 min at 4 °C. Red blood cells were lysed using
155 mM NH4Cl/10 mM KHCO3 buffer (pH 7.4) and
washed with HBSS (PAN Biotech, Germany). After
digestion, leucocytes were depleted with CD45 magnetic
beads (Miltenyi Biotech, Germany) and stained with
fluorochrome-labelled monoclonal antibodies and sorted by
a BD ARIAIII cell sorter (Becton Dickinson, San Jose, CA,
USA). PαS MSC were defined as positive for CD140a and
Sca-1 and negative for CD45 and TER119 and were ex-
panded in PureCoat Amine plates/flasks (BD, Germany) in
alpha-MEM medium supplemented with L-Glutamine, 5 %
FBS (mesenchymal stem cell-qualified, Life technologies,
Germany), and 5 % human platelet lysate. Medium was
changed every 3–7 days depending on cell growth. Human
platelet lysate was prepared as previously described [24].
Lung preparation
Lung single cell suspensions (lung homogenates) were
prepared after enzymatic digestion as previously described
in detail [23]. In brief, the mice were euthanized and the
lungs were perfused via the right ventricle with HBSS
(PAA, Germany) to remove the intravascular pool of cells.
The tissues were minced and digestion was performed in
0.09 U/ml type A collagenase (Roche, Germany) and 9.09
U/ml DNase (Roche, Germany) in IMDM (PAA,
Germany) with 10 % FCS (PAA, Germany) at 37 °C for
1 h. The single cell suspensions were prepared by tissue
resuspension with 20 G 1 ½ cannulas (0.9 × 40 mm; BD,
Germany) and by mashing through a 70 μM cell strainer
(BD, Germany). Red blood cells were lysed by ammonium
chloride lysis. The cells were washed with HBSS for flow
cytometry staining, or the leukocytes were magnetic-bead
sorted after washing with PBS/2 % BSA/2 mM EDTA
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(PAA, Germany). Bronchoalveolar lavages (BAL) were
performed as previously described [25]. The bacterial load
in lung homogenates and BAL were defined by preparing
a two-fold dilution series in sterile HBSS after centrifuga-
tion (2500 g, 15 min, 4 ° C) according to the method de-
veloped by Schott [26].
Flow cytometry
Cellular phenotyping and sorting were performed on a
BD ARIAIII cell sorter (Becton Dickinson, San Jose, CA,
USA). The following fluorochrome-labelled mAbs conju-
gated to FITC, PE, PeCy7, PerCPCy5.5, APC, APC-Cy7,
Brilliant Violet 510, Brilliant Violet 605, Pacific Blue and
Alexa700 or appropriate isotype controls were used for
cell surface staining: CD11b, CD11c, CD45 (clone 30-
F1), CD86, CD103, CD140a (clone APA5), CD274 (PD-
L1), MHC-class II (I-Ab), GR-1, F4/80, NK1.1, SCA-1
(clone D7), Siglec-F (BD Biosciences, Germany), TER119
and 120G8 (Dendritics, France). The surface staining
time was 30 min on ice and cells were washed with
staining buffer (1× HBSS, PAA, Germany) at 400 g for
5 min at room temperature (RT) before analysis. The
number of acquired events was ≥ 500,000.
The viability of sorted cells was >90 % as indicated by
Sytox blue (Life Technologies, Germany) staining. All
mAbs were ordered from Biolegend, Germany unless
indicated otherwise. Absolute cell counts were deter-
mined with AccuCount Fluorescent Particles 7.7 μm
(Spherotech, Lake Forest, USA).
CD4 T cell proliferation assay
CD4+ T cells were isolated from the spleens of OT-II
mice (B6.Cg-Tg(TcraTcrb)425Cbn/J) using the CD4+ T
Cell Isolation Kit (Miltenyi Biotec, Germany). CD4+ T
cells were labeled with 0,5 μM CFSE (eBioscience,
Germany) for 15 min at 37 °C with frequent agitation,
then washed before being used in proliferation assays.
DC were generated from C57BL/6 BM hematopoietic
stem cells by culturing for 7 days in 10 ng/ml murine
GM-CSF and 10 ng/ml murine IL-4 as previously de-
scribed [27]. CD4+ T-cells (1 × 105) were cultured with
DC (1 × 104) and MSC (1 × 104) in RPMI 1640 contain-
ing 10 % FCS (PAA, Germany) for 5 days. Ovalbumin
(OVA, 100 μg/ml) protein (Hyglos, Germany) was added
to the culture medium. OVA-specific proliferation was
evaluated as a CFSE dilution by flow cytometry.
Intracellular cytokine and Foxp3 staining
For cytokine staining cells were stimulated for 6 h at 37 °C
with 50 ng/ml PMA (Sigma-Aldrich, Germany), 1 μg/ml
Ionnomycin (Sigma-Aldrich, Germany) and 3 μg/ml bre-
feldin A (eBioscience, Germany) in RPMI with 10 % FBS
(PAA, Germany). For intracellular cytokine or Foxp3
staining samples were first stained for surface antigens,
washed with PBS (PAN Biotech, Germany), and centri-
fuged for 5 min at RT and 400 g. The cell pellets were vor-
texed for dissociation and incubated with fixation/
permeabilization buffer (BD, Germany) 20 min at RT.
After washing twice with 2 ml of permeabilization/wash-
ing buffer (BD, Germany) the cells were resuspended in
100 μl permeabilization buffer. Intracellular mAbs (IFN-γ,
IL-4, IL-10, IL-17 from Biolegend, Germany; Foxp3,
eBioscience, Germany) or isotype controls were added
at the recommended concentrations and incubated
30 min at RT. Cells were washed two times with
permeabilization/washing buffer and immediately ana-
lyzed by flow cytometry. The number of acquired
events was ≥ 500,000.
Respiratory leukocyte subset discrimination
The gating strategy has been described recently with minor
modifications [23]. Briefly, out of the CD45+ cells, neutro-
phils were identified by GR1brightCD11bbright expression.
Subsequently, out of the neutrophil negative fraction, mac-
rophages were identified as SiglecF++/CD11c positive cells.
DC were identified according to CD11c+Siglec-Fneg
NK1.1neg expression to exclude autofluorescent macro-
phages and NK cells. Then they were further dissected into
plasmacytoid DC (120 g8+ CD11bneg) and after MHC-class
II+ gating into CD103 DC (CD103+ CD11bneg) and CD11b
DC (CD11b+ CD103neg). CD3+ T cells and CD19+ B cells
were identified within the CD45+ SSClow fraction. Out of
the CD3+ T cell fraction, CD4+ and CD8+ T cells were
identified on the basis of CD4 and CD8 expression, re-
spectively. NK cells were identified as CD3neg NK1.1+ cells
and γδ T cells were identified as CD3+ γδ TCR+ cells
(Additional file 1: Figure S1). T regulatory cells were iden-
tified as CD3+CD4+CD25+Foxp3+ cells.
BAL protein and cytokine quantification
Protein quantification was performed with Pierce BCA
Protein Assay Kit (Thermo Scientific, Germany). Mouse
TNF-α, IL-10 and IL-12p70 were quantified by cytomet-
ric bead arrays according to the manufacturer’s instruc-
tions (Flowcytomix, eBioscience, Germany.
Statistical analyses
Statistical analyses were performed using the GraphPad
Prism software version 5.02 (Graphpad Software, Inc.,
USA). The significance of any differences between
groups were analyzed by the one-way ANOVA and
Tukey post-test for multiple comparisons. Survival curve
comparison and analysis was performed using the log-
rank test. A p-value of < 0.05 was considered statistically
significant.
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Results
Prospective high-purity PαS MSC isolation and in vitro
expansion
In the BM of C57BL/6 mice less than 0.1 % of nucleated
cells exhibited the phenotype of PαS MSC (CD45neg
TER119neg CD140a+ SCA-1+; Fig. 1a). PαS MSC were
purified via FACS sorting to a final purity of >98 %
(Fig. 1b). Due to the high purity sorting procedure, the cell
yield per mouse was low (range 180–400 PαS MSC per
mouse). PαS MSC were then grown in vitro for 20–40
days (Fig. 1c). They exhibited a spindle-shaped morph-
ology (Fig. 1d) and inhibited T-cell proliferation in an
antigen-specific T proliferation assay with OVA-pulsed
DC and transgenic OVA-TCR specific CD4+ responder T
cells (Fig. 1e). PαS MSC retained their expression of
CD140a (PDFGRα) and SCA-1 (Fig. 1f). In addition, ex-
tended phenotypic analysis of expanded PαS MSC
revealed homogenous expression of the MSC markers
CD29, CD49e, CD90 and CD105 and the absence of the
HSC/endothelial marker CD34, the leukocyte markers
CD45, CD49b, the endothelial markers CD309, Tie-2 and
the erythroid marker TER119 (Fig. 1f).
PαS MSC inhibit acute alveolitis and lung injury after K.
pneumoniae infection
At 4 h after induction of respiratory K. pneumoniae in-
fection, the animals intratracheally received 1 × 106 PαS
MSC that were resuspended in NaCl or a negative con-
trol (NaCl). Irrespective of PαS MSC treatment, the in-
fected animals exhibited a marked reduction of body
weight within 48 h p.i. representing an indirect sign of
disease (Fig. 2a). Dissection of major alveolar leukocyte
subsets indicated a significant inhibition of acute alveol-
itis by PαS MSC treatment (Fig. 2b-e). Furthermore,
Fig. 1 Purification and expansion of PαS MSC. Representative flow cytometry results of PαS MSC before (a) and after (b) cell sorting. Representative
expansion kinetic of 3000 PαS MSC (n = 4) (c) and phase contrast micrographs of CFU-Fs 28 days after plating (d). T-cell inhibitory capacity of PαS MSC
versus non-MSC control (“CD45neg PαSneg”: CD45neg TER119neg SCA-1neg CD140aneg) added to ovalbumin-pulsed DC in a CFSE T cell proliferation assay
with OVA-TCR specific CD4+ T cells as described in the Methods section. Positive control are Ovalbumin-pulsed DC plus OVA-TCR specific CD4+ T cells
and negative control are DC plus OVA-TCR specific CD4+ T cells without OVA (n = 3; (e). Representative phenotype of PαS MSC after in vitro expansion
before intratracheal application after staining with isotype control (blue) and indicated mAbs (red; f). *p < 0.05, ***p < 0.001; data from n≥ 4 (a-d), or
n = 2 (e, f) experiments
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analysis of alveolar protein content as a measure of al-
veolar protein permeability and fluid clearance revealed
that it was significantly reduced indicating less severe
acute lung injury (p < 0.001, 48 h p.i.; Fig. 2f ). Because
the protein content represents a rather crude measure-
ment of alveolar injury and inflammation we specifically
determined the major pro-inflammatory cytokines TNFα
and IL-12p70 and the immunoregulatory cytokine IL-10
(Fig. 2g-i). PαS MSC treatment significantly inhibited
both alveolar TNFα (p < 0.01) and IL-12p70 (p < 0.05)
whereas IL-10 was unaffected. These data suggest that
PαS MSC treatment inhibited K. pneumoniae-induced
alveolar cellular inflammation, functional deterioration
and pro-inflammatory cytokine production. In addition,
histopathological analysis (Fig. 3) indicated severe sup-
purative and necrotizing pleuritis and steatitis admixed
with myriads of bacteria in contrast to MSC-treated ani-
mals that did not display pleuritic, steatitis or bacteria
on the lung surface or in the mediastinal fat tissue.
Bacteriae were almost absent in MSC-treated animals
but abundant in the mock-treated controls.
PαS MSC inhibit respiratory leukocytosis and DC infiltration
after K. pneumoniae infection
In addition to the isolated alveolar compartment ana-
lysis we extended the analysis to all major leukocyte
subsets in lung homogenates by using multiparameter
flow cytometry during the acute (48 h p.i) and post-
acute (d5 p.i) K. pneumoniae infection to better under-
stand the modulation of the lung inflammatory process
(Fig. 4). PαS MSC treatment significantly suppressed
granulocyte (p < 0.001, 48 h p.i) and DC infiltration
Fig. 2 PαS MSC inhibit alveolar TNF-α, IL-12p70 and acute lung injury after K. pneumoniae infection. K. pneumoniae infected animals were treated
with PαS MSC (4 h p.i.). Analysis of body weight (a) and flow cytometry-based quantitation of alveolar leukocytes, granulocytes and macrophages
(b-e). Alveolar protein (f) and alveolar cytokines TNF-α (g), IL-12p70 (h) and IL-10 (i) were quantified by cytometric bead array. Mean ± SEM; n ≥ 3
(a, c-e); n≥ 4 (f); n ≥ 6 (g-i). *p < 0.05; **p < 0.01; ***p < 0.001 versus mock-treated infected controls. Data from n ≥ 2 (a-i) experiments. Kpn,
infected with K. pneumoniae
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indicating reduced inflammation (p < 0.001, d5 p.i). Dissec-
tion of respiratory DC subsets into plasmacytoid DC,
CD103+ DC and CD11b+ DC revealed a significant sup-
pression of plasmacytoid DC infiltration early after infec-
tion (p < 0.001, 48 h p.i) and of plasmacytoid DC, CD103+
DC and CD11b+ DC late after infection (p < 0.01, d5 p.i). In
contrast, respiratory B lymphocytes and CD4+ and CD8+ T
lymphocytes were not significantly affected. In addition,
with respect to innate lymphocytes, PαS MSC treatment
significantly suppressed respiratory γδ-TCR+ T cell num-
bers 48 h p.i. (p < 0.001) but not NK cells.
PαS MSC inhibit CD86 costimulatory molecule expression
on lung CD103+ DC during acute K. pneumoniae infection
Given the observation, that PαS MSC treatment signifi-
cantly inhibited lung DC infiltration we questioned
whether surface expression of the functionally relevant
costimulatory molecule CD86, the immunoregulatory
Fig. 3 Histopathological analysis of MSC–treated animals after K. pneumoniae infection. Lungs were harvested, fixed in formalin, and embedded in
paraffin and 2 μm sections were prepared and stained with hematoxylin and eosin (a, b, d) or Giemsa (c) for histopathological analyses of MSC-treated
versus mock-treated (NaCl) controls animals after K. pneumoniae infection (d2 p.i.). a K. pneumoniae induced suppurative and necrotizing pneumonia
with a similar distribution of lung lesions in both groups. b, c Infected NaCl-treated controls showed severe suppurative and necrotizing pleuritis
(b, arrowhead) and steatitis (c), admixed with myriads of bacteria, whilst MSC-treated animals displayed neither pleuritic, steatitis nor bacteria
on the lung surface or in the mediastinal fat tissue. d In K. pneumoniae-infected NaCl-treated controls, neutrophils and histiocytes were
predominantly located at the interstitium of the lungs (arrowhead) whereas in MCS-treated lungs, neutrophils were also present in alveolar
spaces (arrowhead) consistent with suppurative bronchopneumonia. Representative images are shown (n = 3 experiments). Bar (a), 2 mm. Bar
(b, d), 50 μm. Bar (c), 20 μm
Hackstein et al. Respiratory Research  (2015) 16:123 Page 6 of 12
molecule PD-L1 (CD274) and MHC-class II were af-
fected by PαS MSC treatment of lung DC subsets
(Fig. 5a-b). These analyses revealed a significant suppres-
sion of CD86 expression on CD103+ DC early after in-
fection (p < 0.001, 48 h p.i.) in contrast to later time
points (d5 p.i.)
PαS MSC inhibit post-infectious expansion of lung pro-
inflammatory IFN-γ+ and IL-17+ T cells without affecting
respiratory T regulatory cells
The identification of reduced DC infiltration and im-
paired CD103+ DC costimulatory molecule expression
raised the question whether PαS MSC treatment inter-
fered also with the post-infectious expansion of polar-
ized T cells (Fig. 6a-c). The results indicated that PαS
MSC treatment significantly inhibited both the relative
and absolute numbers of lung CD4+ IFN-γ+ and CD4+
IL-17+ T cells (p < 0.05, d5 p.i.) in contrast to IL-4+, IL-
10+ and Foxp3+ CD25+ CD4+ T cells (Additional file 2:
Figure S2). These experiments suggested that PαS MSC
treatment modulated adaptive immunity by impairing
pro-inflammatory IL-17 and IFN-γ expressing T cell
subsets.
PαS MSC improve pneumonia survival and do not increase
bacterial load
PαS MSC treatment after respiratory K. pneumoniae
infection resulted in significantly improved overall sur-
vival in comparison to mock-treated (NaCl only) animals
(Fig. 7a). To assess whether the positive results of PαS
MSC may be related to an unspecific cellular effect we
performed experiments with MLg fibroblasts instead of
PαS MSC. Most MLg fibroblast-treated animals died
within 24 h p.i. resulting in significantly reduced survival
in comparison to both PαS MSC and NaCl-only treated
animals (p < 0.01; Fig. 7a).
With respect to the markedly impaired respiratory in-
flammation and reduced numbers of pro-inflammatory
T cells PαS MSC may exert immunosuppressive activity
and might increase bacterial loads after infection.
Fig. 4 PαS MSC treatment modulates respiratory leukocyte subsets after K. pneumoniae infection. Representative flow cytometry analysis of
respiratory leukocytes, granulocytes, macrophages, DC, pDC, CD103+ DC, CD11b+ DC, B cells, CD3+ CD4+ T cells, CD3+ CD8+ T cells, NK cells and
γδ T cells in lung homogenates of K. pneumoniae-infected (Kpn) animals at different timepoints p.i. treated with PαS MSC versus mock-treated
infected animals or uninfected.controls. Mean ± SEM; n ≥ 6 (48 h p.i.); n ≥ 4 (d5 p.i.). **p < 0.01; ***p < 0.001 versus mock-treated infected controls.
Data from n≥ 3 experiments
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Accordingly, we determined the bacterial loads in lung
homogenates and BAL at different time points after K.
pneumoniae infection (Fig. 7b-c). The results consist-
ently showed that PαS MSC treatment did not result in
increased bacterial loads in lung homogenates or in
BAL, indicating that PαS MSC are unlikely to impair
antibacterial immunity.
Discussion
In this study we report on the immunomodulatory cap-
acity of prospectively defined MSC in a preclinical mouse
model of acute bacterial pneumonia. Many studies have
highlighted the immunomodulatory capacity of MSC but
most, if not all studies have used heterogeneous mixtures
of starting cells for the in vitro expansion of MSC. Re-
cently Matsuzaki et al. has identified a BM-derived MSC
subset, expressing PDGFRα and Sca-1, so-called PαS cells,
that are highly enriched for CFU-Fs with differentiation
potential [7]. Here we have demonstrated that these
prospectively defined PαS cells exhibited marked immu-
nomodulatory capacity in vivo. The prospective identifica-
tion of MSC based on surface markers facilitates the
development of standardized protocols and additionally
improves the comparability of scientific studies [4, 8]. In
accordance with Morikawa et al., we have found that cul-
tured PαS cells uniformly expressed conventional MSC
markers CD29, CD49e and SCA-1 and were positive for
CD90 and CD105 [7].
Fig. 5 PαS MSC treatment modulates CD86 costimulatory molecule expression on CD103+ respiratory DC after K. pneumoniae infection.
Representative flow cytometry analysis of CD86, CD274 (PD-L1) and MHC-class II expression on CD103+ respiratory DC in K. pneumoniae-infected
animals treated with PαS MSC versus mock-treated infected animals at 48 h p.i. (a). Quantitative analysis of median fluorescence intensity (MFI) on
respiratory DC subsets in K. pneumoniae-infected (Kpn) animals treated with PαS MSC versus controls at 48 h p.i. (b). Mean ± SEM; n≥ 6 (48 h p.i.);
n≥ 4 (d5 p.i.).***p < 0.001 versus mock-treated infected controls. Data from n = 2 (A-B) experiments
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Fig. 6 PαS MSC suppress in vivo expansion of respiratory IFN-γ+ and IL-17+ CD4+ T cells after K. pneumoniae infection. Representative flow cytometry
analysis of intracellular IL-17 expression in respiratory CD4+ T cells in K. pneumoniae-infected animals treated with PαS MSC versus mock-treated
infected animals at d5 p.i. (a). Iso refers to isotype-matched fluorescence minus-one controls to assess background staining. Relative frequencies and
absolute numbers of cytokine expressing respiratory CD4+ and CD8+ T cell subsets in K. pneumoniae-infected (Kpn) animals treated with PαS MSC
versus mock-treated infected animals (b-c). Mean ± SEM; n≥ 4; *p < 0.05 versus mock-treated infected controls. Data from n≥ 2 (A-C) experiments
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Our results using prospectively defined MSC showed
that expanded PαS cells effectively suppressed acute lung
injury and acute alveolitis caused by respiratory K. pneu-
moniae. We selected a Klebsiella species as the pathogen
because they represent an important group of bacteria
that causes life threatening nosocomial infections [28].
Furthermore, multidrug resistant Klebsiella strains are of
increasing clinical relevance worldwide due to limited
treatment options [29]. We showed that PαS MSC treat-
ment significantly inhibited alveolar protein leakage, gran-
ulocytosis and TNF-α production indicating a marked in
vivo anti-inflammatory capacity. Furthermore, PαS MSC
treatment inhibited not only acute lung injury but add-
itionally suppressed expansion of pro-inflammatory T
helper subsets expressing IL-17 and IFN-γ in the post-
acute pneumonia phase. Our flow cytometry analysis of
respiratory DC subsets provides a rationale for under-
standing the marked inhibition of IL-17 and IFN-γ ex-
pressing T helper cells. Our results suggested that PαS
MSC treatment effectively inhibited accumulation and
CD86 upregulation on respiratory CD103+ DC. Different
reports have highlighted the critical role of CD103+ DC
for the expansion of IL-17 and IFN-γ driven T effector cell
responses [30, 31].
Various studies have investigated the effect of MSC in
models of LPS- or bleomycin-induced lung injury and
have reported significant amelioration after lung injury
[18, 32, 33] as well as a significant survival benefit in
MSC-treated animals [18, 33].
Only a few studies have investigated the therapeutic
activity of MSC in pneumonia models with live bacteria
[19, 20, 34]. Gupta et al. and Kim et al. reported that
intratracheal MSC treatment improved survival and
bacterial clearance in murine Escherichia coli pneumonia
[19, 20]. Here we have extended these findings by using
prospectively defined PαS MSC in a K. pneumonia-
infected animal model. Independent animal models
employing live bacteria are of clinical relevance because
there may be concerns that “immunosuppressive” MSC
might promote bacterial growth due to an impairment
of host defences. Our results using prospectively defined
MSC are in agreement with other data indicating that
intratracheal MSC therapy during infectious pneumonia
promotes rather than inhibits bacterial clearance [19].
Matthay et al. has suggested that the antibacterial effect
of MSC are due to the upregulation of the antibacterial
proteins lipocalin 2 and LL37 [19, 35]. Recent evidence
by Devaney et al. further supports this finding in a rat E.
coli pneumonia model. In their study, MSC-treatment
significantly reduced acute lung injury, improved overall
survival and decreased lung bacterial load. With respect
to the potential anti-bacterial activity of MSC they re-
ported enhanced macrophage phagocytic capacity and
increased lung and systemic concentrations of the anti-
microbial peptide LL37 in MSC-treated animals [34]. In
agreement with these findings, our histopathological
analyses indicated a strikingly reduced number of bac-
teria in the lungs of MSC-treated animals. However,
mean values of bacterial loads were decreased in MSC-
treated animals at d2 and d5 p.i. but these differences were
statistically not significant due to the inter-individual vari-
ation. One may speculate that the antibacterial activity of
MSC may play a key role in models with live bacteria.
With respect to the immunomodulatory activity of MSC,
several studies using different models have reported that
MSC induced increased levels of IL-10 or Foxp3+ regula-
tory T cells [18, 36, 37]. However, in our study both IL-10
production as well as Foxp3+ CD4+ regulatory T cell
frequencies were unaffected after MSC-therapy. Recently,
Bustos et al. reported that pre-activation of human MSC
Fig. 7 PαS MSC improve survival and do not impair bacterial clearance after K. pneumoniae infection. Survival of K. pneumoniae-infected animals
treated with NaCl, PαS MSC or MLg fibroblasts (a). Bacterial load (colony forming units, CFU) of lung homogenate (b) and BAL (c) of K.
pneumoniae-infected (Kpn) animals treated with PαS MSC or NaCl at 48 h and d5 p.i. (a) n ≥ 8, (b, c) mean ± SEM; n≥ 3 per group. **p < 0.01,
***p < 0.001 versus mock-treated infected controls. Data from n≥ 2 (A-C) experiments
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with serum from patients with ARDS markedly increased
their therapeutic capacity in a murine pneumonia model
concomitant with increased IL-10 and IL-1 receptor an-
tagonist levels [38]. Therefore, different levels of MSC
pre-activation in different animal models may impact on
their immunomodulatory capacity. With respect to the
immunosuppressive capacity of MSC we observed signifi-
cantly reduced CD86 surface expression on lung CD103+
DC in MSC-treated animals early after infection. CD86
represents a major T cell costimulatory molecule that is
critically involved in T cell activation [39]. However, CD86
suppression was not significantly suppressed on CD11b +
DC which may be related to different costimulatory mol-
ecule expression kinetics or differential migratory kinetics
of CD11b +DC into inflamed tissue areas.
In summary, we have investigated the in vivo immuno-
modulatory capacity of prospectively defined, purified
PαS MSC in a clinically relevant K. pneumoniae model.
PαS MSC efficiently suppressed acute lung injury and
promoted overall pneumonia survival. Flow cytometry
analysis revealed impaired lung DC infiltration and
CD103+ DC maturation representing known key drivers
of T cell-mediated inflammation, which provided a ra-
tionale for the sustained anti-inflammatory effects of
MSC therapy. These findings support the potential of
using prospectively defined MSC-based therapies for
patients with acute bacterial pneumonia and provide
new insight into the immunomodulatory capacity of PαS
cells.
Conclusions
This experimental animal study has analyzed the in vivo
immunomodulatory activity of prospectively defined MSC
in acute bacterial pneumonia. In most published studies,
MSC have been retrospectively defined based on their
plastic adherent properties leading to heterogeneous cell
populations. Our results indicate that intratracheal appli-
cation of MSC effectively inhibit K.pneumoniae-induced
acute lung injury and respiratory inflammation and pro-
vide additional evidence for the therapeutic activity of
MSC in bacterial pneumonia.
Additional files
Additional file 1: Figure S1. Gating strategy for the identification of
respiratory leukocyte subsets. Respiratory leukocytes were identified using
CD45 surface expression. Respiratory lymphocytes were identified
according to low side scatter characteristics and subsequently discriminated
into CD19+ B cells, NK1.1+ NK cells, CD3+ γδ TCR+ gamma-delta T cells,
CD3+ CD4+ T cells and CD3+ CD8+ T cells. Granulocytes and alveolar
macrophages were subsequently identified out of CD45+ leukocytes based
on CD11b and GR-1 expression (granulocytes) and CD11c and Siglec F
surface expression (alveolar macrophages). DC subsets were subsequently
identified out of CD45+ leukocytes based on CD11c expression in
SiglecF/NK1.1/Gr1 negative cells to exclude contamination by alveolar
macrophages, NK cells and granulocytes. This CD11c positive fraction
was further discriminated into CD103+ DC and CD11b DC based on
MHC-class II, CD103 and CD11b expression as well as in pDC based
on 120 g8 expression and absence of CD11b. Representative figure
from n > 10 experiments. (PDF 382 kb)
Additional file 2: Figure S2. Modulation of respiratory CD4+ CD25+
Foxp3+ regulatory T cells after PαS MSC treatment. Representative flow
cytometry analysis of CD4+ CD25+ Foxp3+ regulatory T cells in K.
pneumoniae-infected animals treated with PαS MSC versus mock-treated
infected animals (A, d5 p.i.). Iso refers to isotype-matched fluorescence
minus-one controls to assess background staining. The frequency in %
refers to the frequency of CD4+ CD25+ Foxp3+ T cells among all CD4+ T
cells. Relative frequencies and absolute numbers of respiratory CD4+
CD25+ Foxp3+ regulatory T cells in K. pneumoniae-infected (Kpn) animals
treated with PαS MSC versus mock-treated infected animals (B). Mean ±
SEM; n≥ 4. Data from n = 2 (A-B) experiments. (PDF 238 kb)
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